Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy

• Published in: Journal of immunotherapy (1997) Vol. 36; no. 9; p. 477
• Main Authors: Lechner, Melissa G, Karimi, Saman S, Barry-Holson, Keegan, Angell, Trevor E, Murphy, Katherine A, Church, Connor H, Ohlfest, John R, Hu, Peisheng, Epstein, Alan L
• Format: Journal Article
• Language: English
• Published: United States 01.11.2013
• Subjects: Animals; Animals, Newborn; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Arginase - genetics; Arginase - metabolism; Cancer Vaccines - immunology; Cancer Vaccines - therapeutic use; Cell Line, Tumor; Cytokines - genetics; Cytokines - immunology; Cytokines - metabolism; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic - drug effects; Gene Expression Regulation, Neoplastic - immunology; Humans; Immunohistochemistry; Immunotherapy - methods; Lymphoid Tissue - drug effects; Lymphoid Tissue - immunology; Lymphoid Tissue - metabolism; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid Cells - drug effects; Myeloid Cells - immunology; Myeloid Cells - metabolism; Neoplasms, Experimental - immunology; Neoplasms, Experimental - therapy; Nitric Oxide Synthase Type II - genetics; Nitric Oxide Synthase Type II - metabolism; Outcome Assessment (Health Care) - methods; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Regulatory - drug effects; T-Lymphocytes, Regulatory - immunology; T-Lymphocytes, Regulatory - metabolism; Tumor Microenvironment - drug effects; Tumor Microenvironment - immunology

Immune profiling has been widely used to probe mechanisms of immune escape in cancer and identify novel targets for therapy. Two emerging uses of immune signatures are to identify likely responders to immunotherapy regimens among individuals with cancer and to understand the variable responses seen...